Avicanna Stock Quote AVCN - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

0.27

Bid

0.265

Ask

0.275

Volume

13,023

0.27 Day's Range 0.28

0.225 52 Week Range 0.60

Market Cap

20.237M

Previous Close

0.275

Open

0.28

Last Trade

1500

0.27

Last Trade Time

10:29:13

Financial Volume

VWAP

Average Volume (3m)

146,520

Shares Outstanding

74,953,000

Dividend Yield

PE Ratio

-2.32

Earnings Per Share (EPS)

-0.12

Revenue

16.79M

Net Profit

-8.74M

Sector

Medicinal Chems,botanicl Pds

Industry

Medicinal Chems,botanicl Pds

Website

www.avicanna.com

Headquarters

Toronto, Ontario, Can

Founded

1970

Avicanna Inc is listed in the Medicinal Chems,botanicl Pds sector of the Toronto Stock Exchange with ticker AVCN. The last closing price for Avicanna was $0.28. Over the last year, Avicanna shares have traded in a share price range of $ 0.225 to $ 0.60.

Avicanna currently has 74,953,000 shares outstanding. The market capitalization of Avicanna is $20.24 million. Avicanna has a price to earnings ratio (PE ratio) of -2.32.

Avicanna General Meeting

TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing...

Avicanna Announces USPTO Issuance of Patent SEDDS Technology

TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing...

Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter

Best Quarterly Results in Company’s History from a Financial Perspective.EBITDA Improvements Driven by Record Revenues, Record Margins and Operational Efficiencies.Marketing Authorization of...

Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa

The study conducted at The Hospital for Sick Children evaluated wound healing, pain, and itch.55% of patients enrolled in Study reported improvements in wound healing, 45% displayed wound...

Avicanna Announces Closing of Non-brokered Private Placement

TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development...

Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study

TORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development...

Avicanna Reports Full Year 2023 Audited Financial Results

$16.8M in Revenue, representing an increase of 314% from 2022$6.7M Consolidated gross Profit, representing an increase of 500% from 2022 TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc...

Avicanna Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation

The 10% CBD (THC free) proprietary oral formulation branded as RHO Phyto Micro Drop 100 in Canada RHO Phyto Micro Drop 100 is available exclusively at MyMedi.ca. TORONTO, March 27, 2024 (GLOBE...